Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360168 | 0.86 | KDM4E (0.77) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL6359528 | 0.83 | KDM4E (0.88) | KDM4ESMN1; SMN2RAB9ANPC1HPGD | |
| Hydrochloric Acid SCHEMBL11633248 | 0.82 | KDM4E (0.59) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL13593756 | 0.82 | KDM4E (0.59) | KDM4ESMN1; SMN2RAB9ACYP1A2HPGD | |
| SCHEMBL9755022 | 0.82 | KDM4E (0.97) | KDM4ESMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL7724527 | 0.82 | KDM4E (0.58) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL10674362 | 0.81 | KDM4E (0.67) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL509136 | 0.81 | SMN1; SMN2 (0.61) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL10671618 | 0.81 | SMN1; SMN2 (0.61) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL10668907 | 0.81 | SMN1; SMN2 (0.61) | KDM4ESMN1; SMN2RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573914-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2017-04-19 | — | — | CN | claimed |
| EP-1778643-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-05-02 | — | — | EP | claimed |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006018260-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H 3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-113264921-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20220289736-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-09-15 | — | — | US | disclosed |
| CN-104448700-B | Resin combination | 味之素株式会社 | 2019-01-22 | — | — | CN | disclosed |
| US-6902902-B2 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-20040127506-A1 | Antimycobacterial compounds | YATVIN MILTON B (US) | 2004-07-01 | — | — | US | disclosed |
| US-6664257-B2 | Such as derivatives of n-butyl-pyrazinamide for treatment of tuberculosis | ENZREL INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030100569-A1 | Anti-mycobacterial compounds | ENZREL INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003039457-A2 | ANTI-MYCOBACTERIAL COMPOUNDS | ENZREL, INC (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | KDM4E 3882/4885SMN1; SMN2 3393/4885RAB9A 2621/4885 |
| US-20220289736-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | KDM4E 3882/4885SMN1; SMN2 3393/4885RAB9A 2621/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | KDM4E 3486/4885SMN1; SMN2 1613/4885RAB9A 1862/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | KDM4E 3882/4885SMN1; SMN2 3393/4885RAB9A 2621/4885 |
| US-20040127506-A1 | Antimycobacterial compounds | IMMT, MT-ND5, ACAT1 | KDM4E 3140/4885SMN1; SMN2 4298/4885RAB9A 1983/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | KDM4E 3882/4885SMN1; SMN2 3393/4885RAB9A 2621/4885 |
| US-20030100569-A1 | Anti-mycobacterial compounds | IMMT, PML, TBC1D5 | KDM4E 2628/4885SMN1; SMN2 4267/4885RAB9A 1499/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | KDM4E 3486/4885SMN1; SMN2 1613/4885RAB9A 1862/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | KDM4E 3486/4885SMN1; SMN2 1613/4885RAB9A 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.